ArticleTranslational vision science & technology2025
Photoreceptor Outer Segment Reflectivity With Ultrahigh-Resolution Visible-Light Optical Coherence Tomography in Systemic Hydroxychloroquine Use.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Optical Coherence Tomography and Angiography in Hydroxychloroquine Retinopathy: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Visible Light Optical Coherence Tomography: Technology and Biomedical Applications.Bioengineering (Basel, Switzerland) · 2025Review
- The path to clinical translation for visible light optical coherence tomography in retinal imaging.Taiwan journal of ophthalmologyReview
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
Purpose: To evaluate outer retinal organization in normal subjects and those using hydroxychloroquine (HCQ) with ultrahigh-resolution visible-light optical coherence tomography (VIS-OCT). Methods: Forty eyes of 22 adult subjects were recruited from a tertiary-care retina practice, including controls (20 eyes, 12 subjects, 40 ± 22 years old) and subjects with a history of HCQ use (20 eyes, 10 subjects, 62 ± 17 years old). Each subject was imaged using a custom-built VIS-OCT device (axial resolution 1.3 µm) and U.S. Food and Drug Administration-approved OCT devices. Results: With the use of VIS-OCT, control subjects demonstrated five and six hyperreflective bands in the foveal and parafoveal regions, respectively, between the outer nuclear layer and Bruch's membrane. These bands demonstrated intensity profiles complementary to the known histopathologic distribution of rods and cones. In comparison to controls, subjects taking HCQ demonstrated reduced intensity of all bands, particularly bands two to four. In all cases of suspected or known toxicity, VIS-OCT demonstrated attenuation of band 3i, and in no cases was there attenuation of other bands that was more severe than band 3i, suggesting that changes in the reflectivity of band 3i may be the earliest identifiable sign of HCQ toxicity. Conclusions: VIS-OCT of the outer retina revealed a unique outer retinal banding pattern corresponding to photoreceptor density distributions. Notable attenuation of the photoreceptor outer segment reflectivity profile was associated with early HCQ toxicity. This finding may be an early, and possibly reversible, sign of HCQ toxicity, primarily impacting the cones. Translational Relevance: VIS-OCT is useful in detecting subclinical outer retinal structural changes found in subjects using hydroxychloroquine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.